Last reviewed · How we verify
NCT06958484
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Phase 2 trial testing Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab in HCC - Hepatocellular Carcinoma in 60 participants. Not yet recruiting.
1 October 2026
Quick facts
| Lead sponsor | The Affiliated Hospital of Xuzhou Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab — full drug profile →
Conditions studied
- HCC - Hepatocellular Carcinoma — all drugs for HCC - Hepatocellular Carcinoma →
- Adjuvant Treatment — all drugs for Adjuvant Treatment →
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Who can join
Adults 18 to 75, any sex, with HCC - Hepatocellular Carcinoma or Adjuvant Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06958484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HCC - Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT07521852 — A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination Wi · Phase 2 · recruiting
- NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
- NCT07310173 — Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07285850 — The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD · Phase 2, PHASE3 · recruiting
- NCT06999837 — [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Model · NA · recruiting
Other The Affiliated Hospital of Xuzhou Medical University trials
Trials by the same sponsor.
- NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
- NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
- NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
- NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
- NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06958484 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06958484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing